Literature DB >> 8793599

Pharmacokinetics of pantoprazole in man.

R Huber1, M Hartmann, H Bliesath, R Lühmann, V W Steinijans, K Zech.   

Abstract

The proton pump inhibitor pantoprazole is a substituted benzimidazole sulphoxide for the treatment of acid-related gastrointestinal diseases such as reflux esophagitis, duodenal and gastric ulcers. Pantoprazole, administered as a 40 mg enteric coated tablet, is quantitatively absorbed. Its absolute bioavailability is 77% and does not change upon multiple dosing. Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h. The AUC(0,inf.) is approximately 5 mgxh/l. Pantoprazole shows linear pharmacokinetics after both i.v. and oral administration. Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins. Elimination half-life, clearance and volume of distribution are independent of the dose. The main serum metabolite is formed by demethylation at the 4-position of the pyridine ring, followed by conjugation with sulphate. Almost 80% of an oral or intravenous dose is excreted as metabolites in urine; the remainder is found in feces and originates from biliary secretion. The pharmacokinetics of pantoprazole are unaltered in patients with renal failure. In patients with severe liver cirrhosis, the decreased rate of metabolism results in a half-life of 7-9 h. The clearance of pantoprazole is only slightly affected by age, its half-life being approximately 1.25 h in the elderly. Concomitant intake of food had no influence on the bioavailability of pantoprazole. Pantoprazole showed lack of cytochrome P450 interaction with concomitantly administered drugs in any of the studies conducted to date. Lack of interaction was also demonstrated with a coadministered antacid. The absence of inductive effects on metabolism after chronic administration was first shown by using antipyrine as a probe for mixed functional oxidative cytochrome P450 enzymes. Absence of CYP1A2 induction was confirmed using the specific probe caffeine. As sensitive probes for CYP3A enzyme induction, urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol were also unchanged.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8793599

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  11 in total

1.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

2.  Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test.

Authors:  Edoardo G Giannini; Federica Malfatti; Federica Botta; Simone Polegato; Emanuela Testa; Alessandra Fumagalli; Mario Mamone; Vincenzo Savarino; Roberto Testa
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

3.  PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis.

Authors:  Mauricio Garcia-Saenz-de-Sicilia; Francisco Sanchez-Avila; Norberto-C Chavez-Tapia; Gustavo Lopez-Arce; Sandra Garcia-Osogobio; Roberto Ruiz-Cordero; Felix-I Tellez-Avila
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

Review 4.  Pharmacokinetics of proton pump inhibitors in children.

Authors:  Catherine Litalien; Yves Théorêt; Christophe Faure
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.

Authors:  K Dilger; Z Zheng; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 6.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

7.  Pantoprazole does not affect performance in traffic-related safety tests: a double-blind, randomised, placebo-controlled, crossover study in healthy volunteers.

Authors:  K W Herberg; M Hartmann; B Neukirchen; R Lühmann; K B Thomas; W Wurst
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

8.  Comparative anti-ulcerogenic study of pantoprazole formulation with and without sodium bicarbonate buffer on pyloric ligated rat.

Authors:  Papiya Bigoniya; A Shukla; C S Singh; P Gotiya
Journal:  J Pharmacol Pharmacother       Date:  2011-07

Review 9.  Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness.

Authors:  Stephen Brett
Journal:  Crit Care       Date:  2004-10-08       Impact factor: 9.097

10.  Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

Authors:  E A Lew; J R Pisegna; J A Starr; E F Soffer; C Forsmark; I M Modlin; J H Walsh; M Beg; W Bochenek; D C Metz
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.